Background: First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice.
introduction Bevacizumab is a humanised monoclonal antibody that specifically inhibits vascular endothelial growth factor (VEGF), a key mediator of angiogenesis [1, 2] . Two large, randomised, phase III trials, E2100 [3] and AVADO [4] , demonstrated significantly improved progression-free survival (PFS; primary end point) and response rates (RRs) when bevacizumab was combined with paclitaxel or docetaxel, respectively, as firstline therapy for locally recurrent or metastatic breast cancer (LR/mBC). In E2100, the hazard ratio for PFS was 0.48 [5] . Median PFS was 11.3 months with the bevacizumab-paclitaxel combination versus 5.8 months with paclitaxel alone. In AVADO, the PFS hazard ratio was 0.67 for bevacizumab 15 mg/kg every 3 weeks combined with docetaxel versus docetaxel-placebo (median 10.0 versus 8.1 months, respectively) [4] . Recently, a third randomised phase III trial (RIBBON-1) in the first-line setting demonstrated significantly improved PFS and RR when bevacizumab was combined with taxane-or anthracycline-based therapy or capecitabine monotherapy [6] .
The combination of bevacizumab with chemotherapy in E2100 and AVADO was associated with a limited increase in the toxicity of chemotherapy. Typical but manageable side-effects of bevacizumab in LR/mBC include hypertension, proteinuria, bleeding and thromboembolic events [3, 4, 7] . In E2100, there was significantly more grade 3/4 infection, fatigue, sensory neuropathy, hypertension, cerebrovascular ischaemia, headache and proteinuria in patients receiving bevacizumab-paclitaxel compared with paclitaxel alone. However, in the placebocontrolled AVADO trial, there was no excess of grade ‡3 infection, venous or arterial thromboembolic events, congestive heart failure (CHF), proteinuria, bleeding or hypertension. Grade ‡3 neuropathy occurred in 3%-4% of patients receiving bevacizumab versus 2% with placebo, suggesting that the higher incidence (24%) with bevacizumab in E2100 was related to prolonged paclitaxel exposure rather than bevacizumab. The incidence of grade ‡3 hypertension with bevacizumab also differed between trials: 15% in E2100 versus 1% and 5% in the 7.5 and 15 mg/kg arms of AVADO, respectively.
The incidence and spectrum of bevacizumab-related sideeffects shows some variation across trials in breast cancer and other common tumour types. It was therefore considered important to conduct a large study (MO19391, ATHENA) to investigate further the safety and efficacy of bevacizumab combined with first-line chemotherapy, usually taxane based, in a broader patient population more closely reflecting general oncology practice.
patients and methods

study design
The primary objective of this open-label, single-arm, international study was to assess the safety profile of bevacizumab combined with first-line taxane monotherapy or combination therapy for LR/mBC, determined by the incidence of National Cancer Institute-Common Toxicity Criteria for Adverse Events (version 3.0) [8] grade 1-5 adverse events (AEs) and serious adverse events (SAEs). Secondary objectives were to assess (i) the efficacy [time to progression (TtP) and overall survival (OS)] of bevacizumab plus taxane-based therapy in this setting and (ii) the safety of bevacizumab in patients developing central nervous system (CNS) metastases during or within 6 months of completing study treatment. RR was also analysed using information from the case report form (CRF). A French substudy evaluating biomarkers and VEGF-A constitutional polymorphisms has been reported separately [9, 10] .
All patients provided written informed consent before undergoing studyspecific procedures. The study design and conduct and the informed consent document were approved by independent ethics committees.
eligibility criteria
The main inclusion criteria for study enrolment were histologically confirmed, human epidermal growth factor receptor 2 (HER2)-negative, LR/mBC (or HER2-positive LR/mBC that had progressed after adjuvant trastuzumab-containing therapy and ineligible for anti-HER2 therapy); age ‡18 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and adequate haematologic, hepatic and renal function. Prior radiotherapy was permitted providing all acute radiotherapy-related toxic effects (except alopecia) had resolved. The principal exclusion criteria were previous chemotherapy for LR/mBC (prior adjuvant chemotherapy permitted); concomitant endocrine therapy for LR/mBC; evidence of CNS metastases (even if previously treated); preexisting peripheral neuropathy grade >2; increased risk of haemorrhage; history of fistula or grade 4 gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment; major surgery within 28 days before starting study therapy; minor surgery within 24 h before the first bevacizumab infusion; unhealed wound, active peptic ulcer or bone fracture; uncontrolled hypertension or pregnancy or breast-feeding. Patients with locally recurrent disease amenable to radiotherapy or resection with curative intent were ineligible.
study treatment
All patients received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (depending on the chemotherapy schedule and physician's preference), usually in combination with taxane-based chemotherapy. The choice of taxane regimen was at the investigator's discretion. If taxanes were contraindicated or not the physician's preference, bevacizumab could be combined with the physician's chosen regimen (excluding anthracyclines). Premedication for chemotherapy was not mandatory. Treatment was continued until disease progression, unacceptable toxicity, clinical judgement to discontinue or withdrawal of patient consent. Concomitant trastuzumab was not permitted. No bevacizumab treatment interruption or dose reduction/escalation was planned. In the event of grade ‡3 bevacizumab-related toxicity, bevacizumab was discontinued temporarily (first occurrence) or permanently (second occurrence). Bevacizumab was discontinued permanently if a patient experienced pulmonary haemorrhage or haemoptysis of any grade, grade ‡3 CNS haemorrhage, any other grade 3 or 4 haemorrhagic event, grade 4 or uncontrolled grade 3 hypertension, reversible posterior leucoencephalopathy syndrome (RPLS), grade 4 thrombosis, any arterial thromboembolic event, any hypersensitivity reaction to bevacizumab, grade 4 proteinuria, gastrointestinal perforation, grade 3/4 bowel obstruction, any wound dehiscence or grade 3/4 left ventricular systolic dysfunction. Chemotherapy interruption and dose modification were implemented according to each clinic's guidelines. If chemotherapy administration was delayed, bevacizumab therapy was also delayed. If chemotherapy was discontinued because of toxicity or patient or physician choice, bevacizumab could be continued as monotherapy. study assessments breast cancer history and tumour biology were recorded. During treatment, all bevacizumab-related AEs were recorded on the electronic CRF. Data were collected for up to 6 months after the last bevacizumab infusion for the following specific AEs previously reported in bevacizumab trials: hypertension, proteinuria, arterial and venous thromboembolic events, CHF, CNS bleeding, other haemorrhages, wound-healing complications, gastrointestinal perforations and fistulae. Additional information on neutropenia and RPLS was collected until deemed unnecessary by the Data Safety Monitoring Board after review of the first 500 patients. Bevacizumab and chemotherapy administration, ECOG PS, AEs, concomitant medications and tumour response were recorded at each cycle. Patients who discontinued bevacizumab but not chemotherapy before disease progression entered a follow-up phase. At the final visit 28 days after the last bevacizumab dose, blood pressure, urinalysis, ECOG PS, AEs (including those of special interest), concomitant therapy and tumour response were recorded. Tumour response and survival status were followed every 3 months after the final visit using modified RECIST criteria. Complete response was defined as the disappearance of all target lesions; partial response was a ‡30% decrease in the sum of the largest diameter (SLD) of target lesions compared with baseline SLD; progressive disease was a ‡20% increase in the SLD of target lesions compared with the smallest recorded SLD. Stable disease was defined as neither sufficient shrinkage to qualify for complete or partial response nor sufficient increase to qualify as progressive disease.
statistical analyses
The planned sample size of 2000 patients allowed investigation and detection of non-frequent AEs. All analyses were carried out on the safety population, comprising all patients with at least one valid post-baseline assessment who received at least one dose of bevacizumab.
Based on an overall study population of 2000 patients, the incidence of uncommon (£1%) SAEs could be estimated within approximately 20.4% to +0.5% and the incidence of SAEs occurring in <5% could be estimated within approximately 21.7% to +2.3% for any subpopulation of 500 patients. Subpopulation analysis based on chemotherapy partner was planned. TtP was defined as the interval between initiating first-line therapy and first recorded disease progression according to the investigator. OS was defined as the interval between starting first-line therapy and death from any cause. Table 1 . Of the 1794 patients initially presenting with early breast cancer, 1696 (94.5%) had received adjuvant or neoadjuvant therapy, including chemotherapy in 88.4%.
treatment exposure
Bevacizumab was typically combined with single-agent paclitaxel (35%) or single-agent docetaxel (33%). The paclitaxel administration schedule was weekly in 17%, every 3 weeks in 13% and other in 6%. A further 10% of patients received taxane-based combination regimens, most commonly with carboplatin or gemcitabine. The non-taxane monotherapies most frequently combined with bevacizumab were capecitabine (5%) and vinorelbine (3%).
The median duration of treatment was 6.2 months for bevacizumab (range 0.0-27.9) and 4.2 months for chemotherapy (range 0.0-29.5). Among 1316 patients whose disease had progressed at the time of data cut-off, 479 (36%) had continued bevacizumab and chemotherapy until disease progression and a further 525 patients (40%) had received single-agent bevacizumab until disease progression after discontinuing chemotherapy. The median duration of single-agent bevacizumab in the latter group was 4.1 months [95% confidence interval (CI) 3.7-4.4] .
safety At the time of data cut-off, 16% of patients had not had their final visit (often because patients were still receiving therapy); 18% had received bevacizumab for >1 year. SAEs (all grades, irrespective of relationship to treatment) were reported in 655 patients (29%) ( Table 2 ). The most frequent SAEs were febrile Annals of Oncology original article neutropenia (5.1%), neutropenia (3.6%) and pyrexia (1.5%). Grade ‡3 AEs in >1% of patients are shown in Table 3, while  Table 4 summarises predefined grade ‡3 AEs of special interest. Bevacizumab was discontinued permanently in 18.9% of patients because of AEs, most commonly hypertension (1.8%), fatigue (1.2%), proteinuria (1.0%), epistaxis (0.8%), pulmonary embolism (0.8%), dyspnoea (0.7%), increased alanine aminotransferase (0.6%), nausea (0.6%) and vomiting (0.5%).
CNS metastases were documented in 205 patients (9.1%) during the study. Four of these patients (2.0%; 0.2% of the entire study population) experienced CNS bleeding during the study or survival follow-up. The median interval between first treatment administration and diagnosis of CNS metastases was 10.5 months (range 0.0-27.3).
To evaluate whether bevacizumab exposure increases the risk of soft tissue and haemorrhagic toxic effects following surgery, post-surgical bleeding events and wound-healing complications were reviewed in the 496 patients who underwent surgery. There were no grade ‡4 bleeding events; grade 3 bleeding was reported in 3 (1.5%) of 194 patients who received major surgery and 2 (0.7%) of 302 patients who underwent minor surgery. Grades 3 and 4 wound-healing complications occurred in 2.6% and 2.0%, respectively (no grade 5). Further details will be reported separately.
efficacy At the time of data cut-off, disease had progressed in 58% of patients. The median TtP was 9.5 months (95% CI 9.1-9.9; Figure 1 ). The overall RR (best response) was 52% in the intent-to-treat (ITT) population. A further 33% achieved stable disease. Patients without tumour assessment or with nonevaluable disease (6%) were counted as non-responders. Among the 2120 patients assessable for response, the best RR was 55%. At data cut-off, 1622 patients (72%) were still alive and survival follow-up is ongoing. The most common cause of death was breast cancer (24%). The remaining deaths were attributed to concurrent illness (0.5%), outcome of AE (0.4%), chemotherapy (0.3%), bevacizumab (0.2%) or other/unknown cause (2.2%).
In the group of 205 patients who developed CNS metastases during the study, median TtP was 7.1 months (95% CI 6.7-7.8) and median OS was 14.6 months (95% CI 13.1-17.0). 
subpopulation analyses
To examine whether the efficacy and safety of bevacizumab varied according to chemotherapy partner, a planned subpopulation analysis was carried out. The majority of patients (78%) received bevacizumab with a taxane (alone or with another chemotherapy). Chemotherapy was switched before evidence of progressive disease in 12% of patients. Typically, the first chemotherapy agent in these patients was docetaxel or taxane combination therapy; the second regimen before progression was a non-taxane regimen in more than half of the patients (most commonly capecitabine). The baseline characteristics of the seven subpopulations were generally balanced, except that the two combination subgroups and the capecitabine monotherapy subgroup included more patients with steroid hormone receptornegative disease, and the capecitabine and vinorelbine monotherapy groups included more patients with a diseasefree interval £24 months. There were no clear differences in bevacizumab-associated AEs between chemotherapy cohorts, except for a higher incidence of grade ‡3 AEs in patients who switched chemotherapy (Table 5 ). Median TtP was longer with taxane-based than non-taxane-containing bevacizumab regimens (Table 5 ) and was longest in patients who switched chemotherapy.
In a second subpopulation analysis assessing the safety and efficacy of bevacizumab in the 175 patients (7.8%) ‡70 years of age, grade ‡3 AEs occurred in 65% versus 59% of younger patients; SAEs occurred in 33% versus 25%, respectively. The RR in the older subgroup was 42% and median TtP was 10.4 months (95% CI 8. 8-11.8) . Details of safety and outcome in the elderly will be reported separately.
A planned subpopulation analysis of patients with ECOG PS of two suggested a slight increase in grade ‡3 AEs and SAEs with worsening PS. However, the incidence of grade ‡3 AEs previously reported with bevacizumab was similar in the subgroups of patients with baseline ECOG PS of zero to one (11%) and two (12%). There was no consistent pattern in the occurrence of specific bevacizumab-related AEs between subgroups. Efficacy was similar between subgroups (median TtP 9.6 and 8.9 months, respectively).
Lastly, the study population included 577 patients with estrogen receptor-, progesterone receptor-and HER2-negative ('triple-negative') tumours. Exploratory subpopulation analysis showed an overall RR of 47% in these patients (ITT population), median TtP of 7.2 months (95% CI 6.5-7.6) and median OS of 19.5 months.
discussion
This report represents the largest study population of patients with LR/mBC receiving bevacizumab-containing therapy in the context of general oncology practice. The results show that first-line bevacizumab in combination with taxane-based therapy is well tolerated with a low incidence of SAEs or specific AEs in a broad population of breast cancer patients. Our safety and efficacy data are consistent with results of the E2100, AVADO and RIBBON-1 phase III trials evaluating bevacizumab in combination with first-line taxane-based therapy for LR/mBC.
The incidence of grade 3/4 hypertension in the present study (4.4%) is considerably lower than in the E2100 trial (16.0%) [3] and very similar to that in AVADO (4.5%) [4] . In AVADO, there was no excess of grade ‡3 hypertension in the bevacizumab-containing arms compared with the placebodocetaxel arm. This discrepancy between E2100 and AVADO may be attributable to differences in AE reporting. In E2100, data on AEs were collected more rigorously in the investigational (bevacizumab) arm than the control arm. The lack of excess hypertension with bevacizumab in the AVADO trial may be explained by the more robust assessment of the impact of bevacizumab achieved with a double-blind, placebocontrolled design. Alternatively, the difference between the two trials may reflect increasing familiarity and improved management of bevacizumab side-effects. The low rates of other grade ‡3 bevacizumab-associated AEs, including CHF (0.4%) and gastrointestinal perforation (0.3%), are consistent with rates reported in previous breast cancer trials. Gastrointestinal perforation is more common in colorectal or late-stage ovarian cancer than breast cancer, possibly partly due to intra-abdominal tumour invasion. The 0.3% incidence in ATHENA compares favourably with a 0.9% incidence reported in a meta-analysis of 12 294 patients receiving bevacizumab for a range of cancer types in 17 randomised trials; an increased risk of gastrointestinal perforation with bevacizumab-versus non-bevacizumabcontaining regimens was observed in the meta-analysis (hazard ratio = 2.14 in the overall population; hazard ratio = 1.63 in the breast cancer trials) [11] . Some reports suggest an increased risk in patients who have undergone pelvic irradiation [12] . CHF, which might be expected more frequently in breast cancer patients than in other tumour types because of adjuvant anthracycline use and/or chest wall irradiation, occurred at grade ‡3 in 0.4% of patients in ATHENA. Apart from these two tumour-specific effects, our findings are consistent with results of similar observational studies evaluating the safety of first-line bevacizumab combined with standard chemotherapy in metastatic colorectal cancer (first BEAT and BRiTE) [13, 14] or non-small-cell lung cancer (SAiL) [15] .
The median TtP in ATHENA was 9.5 months, similar to median PFS values in the phase III trials evaluating the approved bevacizumab dose combined with a taxane (11.3 months in E2100, 10 .0 months in AVADO, 9.2 months in the taxane/anthracycline cohort of RIBBON-1) [4] [5] [6] . Likewise, RR was similar: 52% in ATHENA compared with 50%, 64% and 51%, respectively [4, 6, 16] . These findings therefore support the clinical benefit seen in randomised trials of bevacizumab combined with taxane-based chemotherapy. In the subpopulation of patients with triple-negative disease, median TtP was 7.2 months, consistent with reports that the benefit of bevacizumab in HER2-negative disease is seen irrespective of steroid hormone receptor status [17] . At the time of data cut-off for ATHENA, 72% of patients were still alive and consequently OS data are immature. An updated analysis will be presented at a later date.
An important finding from ATHENA is the feasibility of administering bevacizumab with taxane-based combination therapy, normally associated with greater toxicity than singleagent taxane [18, 19] . Furthermore, although the majority of patients (78%) received bevacizumab in combination with taxane-containing therapy, some received bevacizumab with Variations in the incidences of grade ‡3 AEs with different chemotherapy agents were consistent with the known profiles of each chemotherapy, and no new safety signals for bevacizumab were observed. Median TtP and RR appear to be more favourable among patients receiving taxane-versus non-taxane-based therapy with bevacizumab. However, apparent differences in safety and efficacy according to chemotherapy partner should be interpreted with caution because of the small patient numbers and variation in baseline characteristics between subgroups.
Chemotherapy selection was at the discretion of the investigator and therefore comparison of the subgroups is inappropriate because of potential physician bias. An ongoing randomised trial, TURANDOT, is designed to compare the efficacy of paclitaxel versus capecitabine, both combined with bevacizumab, and should provide valuable information on potential differences between chemotherapy partners [20] . Despite these limitations, the results show that bevacizumab can be effectively and safely combined with a wide range of chemotherapy regimens commonly used as first-line therapy for LR/mBC. This observation is consistent with findings from the RIBBON-1 trial, which showed that bevacizumab combined with standard chemotherapy regimens, including anthracyclinebased therapy or capecitabine, significantly improves PFS compared with chemotherapy alone [6] . In summary, safety and efficacy results from this large observational study of bevacizumab in combination with taxane-based chemotherapy for LR/mBC in the 'real-world' clinical setting are consistent with data from randomised clinical trials in the first-line LR/mBC setting. 
